Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Sarcoma 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Breast Neoplasms 3Prostatic Neoplasms 2Lung Neoplasms 2Stomach Neoplasms 1Sarcoma 1Ovarian Neoplasms 1Neoplasm Metastasis 1Myelodysplastic Syndromes 1Leukemia, Myelomonocytic, Chronic 1Head and Neck Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Anemia, Refractory, with Excess of Blasts 1

Interventions

Doxorubicin 13Gemcitabine 10Cyclophosphamide 10pazopanib 8Filgrastim 8Radiotherapy 7Ifosfamide 7Cisplatin 7Irinotecan 6Docetaxel 6Radiation 5Granulocyte Colony-Stimulating Factor 5Etoposide 5Trabectedin 4Magnetic Resonance Spectroscopy 4Celecoxib 4Busulfan 4Bevacizumab 4Albumin-Bound Paclitaxel 4temsirolimus 3sargramostim 3pembrolizumab 3X-Rays 3Sirolimus 3Radiotherapy, Intensity-Modulated 3Paclitaxel 3Neoadjuvant Therapy 3Leucovorin 3Dexrazoxane 3Cryosurgery 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Terminated × Sarcoma × lonafarnib × Clear all
NCT00288444 2012-12-18

Interaction of Docetaxel and Lonafarnib in Patients With Advanced Cancer

Emory University

Phase 1 Terminated
38 enrolled
BreastGastrointestinalGenitourinarySarcomaThoracic

Breast Neoplasms, Lung Neoplasms, Prostatic Neoplasms, Sarcoma, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡